Hsbc Holdings PLC Makes New Investment in Corcept Therapeutics Incorporated $CORT

Hsbc Holdings PLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,653 shares of the biotechnology company’s stock, valued at approximately $265,000.

A number of other institutional investors have also recently made changes to their positions in CORT. State Street Corp raised its position in shares of Corcept Therapeutics by 0.5% in the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after purchasing an additional 15,656 shares during the period. Geode Capital Management LLC grew its stake in Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares in the last quarter. Morgan Stanley grew its stake in Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after buying an additional 405,081 shares in the last quarter. AQR Capital Management LLC raised its holdings in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the period. Finally, TD Asset Management Inc raised its holdings in Corcept Therapeutics by 4.0% during the 4th quarter. TD Asset Management Inc now owns 994,844 shares of the biotechnology company’s stock valued at $34,621,000 after acquiring an additional 38,708 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept’s latest quarterly results exceeded expectations, with earnings of $0.36 per share versus the $0.02 consensus estimate and revenue of $256.15 million versus $221.15 million expected. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler assigned Corcept an “Overweight” rating, signaling confidence in the company’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $165 price target. The firm raised its FY2026 EPS forecast to $2.15 from $0.80 and increased its Q3 2026 estimate to $0.78 from $0.34, suggesting expectations for significant near-term earnings growth.
• Neutral Sentiment: Brokerages’ average target price is $94.67, materially below the recent $114.49 reference price. This gap indicates analysts have not fully caught up with the rally or see limited upside from current levels. Brokerages Set Corcept Therapeutics Target Price at $94.67
• Negative Sentiment: Despite the bullish rating, HC Wainwright reduced its FY2027 EPS forecast to $3.95 from $5.38 and lowered estimates for Q1–Q4 2027. These revisions raise concerns about the pace of longer-term earnings growth, particularly with CORT trading at a very high valuation.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, June 24th. HC Wainwright boosted their price objective on Corcept Therapeutics from $95.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. Finally, Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.17.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $114.49 on Monday. The firm has a fifty day moving average price of $84.77 and a two-hundred day moving average price of $56.91. The company has a market cap of $12.38 billion, a price-to-earnings ratio of 272.60 and a beta of 0.45. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $122.21.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter in the prior year, the firm posted $0.29 earnings per share. The business’s quarterly revenue was up 31.7% on a year-over-year basis. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider Sean Maduck sold 75,000 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the completion of the transaction, the insider directly owned 8,977 shares in the company, valued at $588,801.43. The trade was a 89.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Guyer sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total value of $1,862,600.00. Following the completion of the transaction, the insider owned 3,985 shares in the company, valued at $371,123.05. This represents a 83.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 300,000 shares of company stock valued at $22,088,050 over the last 90 days. Insiders own 20.70% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.